Abstract
Dibenz[b,f][1,4]oxazepin-11(10H)-ones (III), pyrido[2,3-b] [1,4]benzoxazepin-6(5fl)-ones (IV), and pyrido[2,3-b]-[1,5]benzoxazepin-5(6H)-ones (V) were found to inhibit human immunodeficiency virus type 1 reverse transcriptase with IC50 values as low as 19 nM. A-ring substitution has a profound effect on activity, with appropriate substituents at the positions ortho and para to the lactam nitrogen providing dramatically enhanced potency. Substitution in the C-ring is generally neutral or detrimental to activity. Although a C-ring amino substituent at the position meta to the lactam carbonyl is generally beneficial to activity, it has essentially no effect when the A-ring is optimally substituted. Like the dipyridodiazepinone nevirapine, compounds III-V are specific for HIV-1 RT, exhibiting no inhibitory activity against HIV-2 RT or other virial reverse transcriptase enzymes. © 1992, American Chemical Society. All rights reserved.
Cite
CITATION STYLE
Klunder, J. M., Hargrave, K. D., West, M. A., Cullen, E. E., Pal, K. E., Behnke, M. L., … Adams, J. (1992). Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepinones. Journal of Medicinal Chemistry, 35(10), 1887–1897. https://doi.org/10.1021/jm00088a027
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.